After Cinven deal, Bioclinica starts hiring spree in imaging, biomarkers

The three senior hires comes a few months after the company was bought out by investment firm Cinven

After being bought out last August by London-based investment firm Cinven, Bioclinica has made three senior hires for its medical imaging and biomarkers unit.

The pharma services company said the new appointees are: Andrew Kraus, who comes on board as COO; Souhil Zaim, now head of global medical and science affairs; and Sara Levy, becoming the VP of client services. They will be based at the unit’s global HQ in Princeton, New Jersey.

Kraus comes in from a COO and treasurer role at the Cardiovascular Research Foundation in New York City, while Zaim joins from a long history in the medical imaging industry, including a stint at the University of California at San Francisco. Levy, meanwhile, was most recently the clinical practice director at Penobscot Community Health Center.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

David Herron, president of medical imaging and biomarkers at Bioclinica, said: “I am very happy to have these three, multi-talented individuals join our incredible team, adding their expertise, experience and passion for creating value for patients, customers and the industry.”

Though it does not call itself a CRO, Bioclinica does work with pharma companies in clinical trials, including using its tech for clinical research data and analytics.

The company has been in a deal-hungry mood, more recently signing a deal with ArisGlobal to help run its drug safety monitoring services.

This was just one of a number of deals in the past 18 months, that includes a new tie-up with Japanese CRO EPS to focus on risk-based monitoring in clinical trials, one of six new deals and pacts the company has made since 2014.

In February, last year, it also launched a new internal “Post-Approval Research” division as it looks to take big steps into the growing realm of helping biopharma with data and costs after launch.

Then in August, it was itself snapped up by Cinven, although financial details of the deal were not given.

BioClinica’s profits had grown as a result of its deals, with annual earnings before interest, taxes depreciation and amortization approaching $100 million, according to sources recently speaking to Reuters last year.

It had been owned by JLL Partners, who took ownership back in 2013 for $123 million.

Read more on

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.